Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Metastatic Soft Tissue Sarcoma
NCT01900743Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Jun 2013
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Arm A: Regorafenib with Arm B: Placebo (2 arms). Primary endpoint: Progression-free survival up to 2 years. Started Jun 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01900743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900743.